ClinicalTrials.gg
CompletedNCT00261833Updated Jan 19, 2015Results posted

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

A Phase 4 interventional study of Alpha1-proteinase inhibitor and Placebo in Alpha1-proteinase Inhibitor Deficiency and Emphysema, sponsored by CSL Behring. Completed at 28 sites in 13 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-19.

Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
4th of 25
180 · median 30
Started
2006
with 3 others
Phase 4
6 of 25
1 open now
Registered
2nd of 25
by date
Lead sponsor
2 of 25
CSL Behring

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 4th largest by enrollment, is one of 4 that started in 2006, is one of 6 in phase 4, and was the 2nd registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, double-blind, multicenter phase III/IV study to compare the efficacy and safety of Zemaira® with placebo in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The effect of Zemaira® on the progression of emphysema will be assessed by the decline of lung density, measured by computed tomography (CT).

03

Conditions studied

  • Alpha1-proteinase Inhibitor Deficiency
  • Emphysema

Keywords

  • Alpha1-proteinase inhibitor deficiency
  • Emphysema
  • Chronic augmentation and maintenance therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 years of age and willing to sign .
  • Males and non-pregnant, non-lactating females whose screening pregnancy test is negative and who are using methods deemed reliable by the investigator.
  • Diagnosis of alpha1-proteinase inhibitor (A1-PI) deficiency (serum A1-PI levels \< 11 μM or \< 80 mg/dL). This includes newly diagnosed subjects, previously untreated subjects, currently treated subjects, and subjects currently not on treatment therapy but on treatment in the past.
  • Subjects with emphysema and (FEV1) ≥ 35% and ≤ 70% (predicted).
  • No signs of chronic or acute Hepatitis A, , or infection (negative serologies for HIV and viral hepatitis). In case of positive serologies for viral hepatitis, vaccination status or negative IgM should be available.

Exclusion criteria

Exclusion Criteria:

  • Any relevant chronic diseases or history of relevant diseases (e.g., severe renal insufficiency) except respiratory or liver disease secondary to alpha1-proteinase inhibitor deficiency. Subjects with well-controlled, chronic diseases may be included after consultation with the treating physician and the sponsor.
  • Current evidence of alcohol abuse or history of abuse of illegal and/or legally prescribed drugs such as barbiturates, benzodiazepines, amphetamines, cocaine, opioids, and cannabinoids.
  • History of allergy, anaphylactic reaction, or severe systemic response to human plasma derived products, or known mannitol , or history of prior adverse reaction to mannitol.
  • History of transfusion reactions.
  • Selective IgA deficiency.
  • Acute illness within one week prior to the first administration of the medicinal product (IMP). Start of treatment after recovery is possible.
  • Current tobacco smoker (smoking has to be ceased at least 6 months prior study inclusion). Subjects with a positive cotinine test due to nicotine replacement therapy (e.g. patches, chewing gum) or snuff are eligible.
  • Conditions or behaviors that interfere with attending scheduled study visits in the opinion of the investigator.
  • History of non-compliance.
  • Administration of any other experimental new drug or participation in an investigation of a marketed product within one month prior to the screening visit date.
  • Inability to perform necessary study procedures.
  • Lung transplantation, lung volume reduction surgery or lobectomy or being on a waiting list for any such surgeries.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Zemaira®

    Biological: Alpha1-proteinase inhibitor

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • 60 mg/kg body weight/week intravenous

    Also known as: Zemaira®

  • OtherPlacebo

    Lyophilized preparation: 60 mg/kg body weight/week intravenous

06

What researchers measure

Primary outcomes

  1. Annual Rate of Change in Lung Density

    As measured by centralized, standardized computer tomographic (CT) lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume and are presented as point estimates for the average rate of decline in each treatment group.

    Time frame: Over a 2-year period

Secondary outcomes

  1. Annual Rate of Pulmonary Exacerbations

    Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion. The annual rate was based on the total number of exacerbations and the total number of participant study days for all participants in the specified analysis population and adjusted to 365.25 days.

    Time frame: Over a 2-year period

  2. Percent Change in FEV1

    Percent change from baseline to Month 24.

    Time frame: From baseline to 2 years

  3. Time to First Pulmonary Exacerbation

    Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion.

    Time frame: Over a 2-year period

  4. Change in Lung Density

    Change from baseline to Month 24 as measured by centralized, standardized CT lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume.

    Time frame: From baseline to 2 years

  5. Change in Exercise Capacity

    Exercise capacity was measured as distance walked, using the incremental shuttle walk test. Change from baseline to end of treatment (2 years) in exercise capacity was analysed using an analysis of covariance (ANCOVA).

    Time frame: From baseline to 2 years

  6. Change in Patient-reported Symptoms

    Patient-reported symptoms were measured using the symptoms score component of the St George's Respiratory Questionnaire (SGRQ). SGRQ scores range from 0 to 100, with higher scores indicating more limitations and negative values for change indicating improvement. Change from baseline to end of treatment (2 years) in SGRQ was analysed using an ANCOVA.

    Time frame: From baseline to 2 years

  7. Frequency and Intensity of Adverse Events (AEs)

    Number of participants with at least one AE, and the number of participants with mild, moderate or severe AEs. AE intensity was defined as mild (does not interfere with routine activities), moderate (interferes with routine activities), or severe (impossible to perform routine activities).

    Time frame: Over a 2-year period

  8. Percent Change in Percent Predicted FEV1

    Percent change from baseline to Month 24.

    Time frame: From baseline to 2 years

  9. Percent Change in FEV1 Divided by Forced Vital Capacity

    Percent change from baseline to Month 24.

    Time frame: From baseline to 2 years

  10. Percent Change in DLCO

    Percent change from baseline to Month 24.

    Time frame: From baseline to 2 years

  11. Duration of Pulmonary Exacerbations Relative to Treatment Duration

    Defined as the percentage of total treatment duration across participants for 1) exacerbations overall, 2) antibiotic treatment for exacerbations, and 3) hospitalization for exacerbations. Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion.

    Time frame: Over a 2-year period

  12. Severity of Pulmonary Exacerbations

    Defined as the number of participants requiring 1) antibiotic treatment for exacerbations, and 2) hospitalization for exacerbations. Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion. Antibiotic treatment usage was reported by quarterly interval.

    Time frame: Over a 2-year period

Other outcomes

  1. Baseline Lung Density at Total Lung Capacity (TLC) and Forced Residual Capacity (FRC)

    Time frame: Baseline

07

Results

Posted Jan 19, 2015

Participant flow

This multicenter, multinational study enrolled participants at 28 study centers in Europe, North America, and Australia.

Participant flow — Overall Study
MilestoneZemaira®Placebo
Started9387
Completed8469
Not completed918
Withdrew: Death13
Withdrew: Adverse event14
Withdrew: Withdrawal by subject57
Withdrew: Protocol violation01
Withdrew: Suspicion of pulmonary cancer01
Withdrew: Lung transplantation11
Withdrew: Missing reason10
Withdrew: Not interested in being participant01

Outcome measures

PrimaryAnnual Rate of Change in Lung Density

As measured by centralized, standardized computer tomographic (CT) lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume and are presented as point estimates for the average rate of decline in each treatment group.

Time frame:
Over a 2-year period
Reported as:
Least squares mean · g/L per year
Annual Rate of Change in Lung Density
g/L per yearZemaira®Placebo
TLC + FRC combined-1.50 ± 0.22-2.12 ± 0.24
TLC-1.45 ± 0.23-2.19 ± 0.25
FRC-1.55 ± 0.24-2.02 ± 0.26
Statistical analysis
  • Zemaira® vs Placebo · 95% confidence interval · p = 0.029 (A 1-sided P-value less than 0.025 and a positive estimate of the treatment difference Zemaira minus placebo (ie, the lower bound of the 95% confidence interval \[CI\] being greater than zero) will indicate superiority of Zemaira compared with Placebo.) · Difference in lung density(adjusted p15): 0.618 · 95% CI -0.024 to 1.261A mixed model was used to estimate the 95% CI for the difference (Zemaira® - placebo) in annual lung density decline.
  • Zemaira® vs Placebo · 95% confidence interval · p = 0.017 (A 1-sided P-value less than 0.025 and a positive estimate of the treatment difference Zemaira® minus placebo (ie, the lower bound of the 95% CI being greater than zero) will indicate superiority of Zemaira® compared with Placebo.) · Difference in lung density(adjusted p15): 0.740 · 95% CI 0.059 to 1.420A mixed model was used to estimate the 95% CI for the difference (Zemaira® - placebo) in annual lung density decline.
  • Zemaira® vs Placebo · 95% confidence interval · p = 0.090 (A 1-sided P-value less than 0.025 and a positive estimate of the treatment difference Zemaira® minus placebo (ie, the lower bound of the 95% CI being greater than zero) will indicate superiority of Zemaira® compared with Placebo.) · Difference in lung density(adjusted p15): 0.478 · 95% CI -0.223 to 1.180A mixed model was used to estimate the 95% CI for the difference (Zemaira® - placebo) in annual lung density decline.
SecondaryAnnual Rate of Pulmonary Exacerbations

Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion. The annual rate was based on the total number of exacerbations and the total number of participant study days for all participants in the specified analysis population and adjusted to 365.25 days.

Time frame:
Over a 2-year period
Reported as:
Number · exacerbations per participant year
Annual Rate of Pulmonary Exacerbations
exacerbations per participant yearZemaira®Placebo
Annual Rate of Pulmonary Exacerbations1.70 (1.51 to 1.89)1.42 (1.23 to 1.61)
SecondaryPercent Change in FEV1

Percent change from baseline to Month 24.

Time frame:
From baseline to 2 years
Reported as:
Least squares mean · percent change
Percent Change in FEV1
percent changeZemaira®Placebo
Percent Change in FEV1-4.29 ± 1.26-2.06 ± 1.30
SecondaryTime to First Pulmonary Exacerbation

Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion.

Time frame:
Over a 2-year period
Reported as:
Median · Years
Time to First Pulmonary Exacerbation
YearsZemaira®Placebo
Time to First Pulmonary Exacerbation0.60 (0.33 to 1.11)0.73 (0.46 to 1.17)
SecondaryChange in Lung Density

Change from baseline to Month 24 as measured by centralized, standardized CT lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume.

Time frame:
From baseline to 2 years
Reported as:
Least squares mean · g/L
Change in Lung Density
g/LZemaira®Placebo
TLC + FRC combined-2.33 ± 0.45-3.37 ± 0.50
TLC (N=66 for placebo)-2.22 ± 0.47-3.54 ± 0.52
FRC-2.44 ± 0.50-3.33 ± 0.56
Statistical analysis
  • Zemaira® vs Placebo · 95% confidence interval · p = 0.058 (A 1-sided P-value less than 0.025 and a positive estimate of the treatment difference Zemaira® minus placebo (ie, the lower bound of the 95% CI being greater than zero) will indicate superiority of Zemaira® compared with Placebo.) · Difference in lung density(adjusted p15): 1.04 · 95% CI -0.26 to 2.34A mixed model ANCOVA was used to estimate the 95% CI for the difference (Zemaira® - placebo) in the change in lung density.
  • Zemaira® vs Placebo · 95% confidence interval · p = 0.028 (A 1-sided P-value less than 0.025 and a positive estimate of the treatment difference Zemaira® minus placebo (i.e., the lower bound of the 95% CI being greater than zero) will indicate superiority of Zemaira® compared with Placebo.) · Difference in lung density(adjusted p15): 1.32 · 95% CI -0.03 to 2.67A mixed model ANCOVA was used to estimate the 95% CI for the difference (Zemaira® - placebo) in the change in lung density.
  • Zemaira® vs Placebo · 95% confidence interval · p = 0.115 (A 1-sided P-value less than 0.025 and a positive estimate of the treatment difference Zemaira® minus placebo (ie, the lower bound of the 95% CI being greater than zero) will indicate superiority of Zemaira® compared with Placebo.) · Difference in lung density(adjusted p15): 0.89 · 95% CI -0.57 to 2.34A mixed model ANCOVA was used to estimate the 95% CI for the difference (Zemaira® - placebo) in the change in lung density.
SecondaryChange in Exercise Capacity

Exercise capacity was measured as distance walked, using the incremental shuttle walk test. Change from baseline to end of treatment (2 years) in exercise capacity was analysed using an analysis of covariance (ANCOVA).

Time frame:
From baseline to 2 years
Reported as:
Least squares mean · metre
Change in Exercise Capacity
metreZemaira®Placebo
Change in Exercise Capacity1.77 ± 13.014.86 ± 13.5
SecondaryChange in Patient-reported Symptoms

Patient-reported symptoms were measured using the symptoms score component of the St George's Respiratory Questionnaire (SGRQ). SGRQ scores range from 0 to 100, with higher scores indicating more limitations and negative values for change indicating improvement. Change from baseline to end of treatment (2 years) in SGRQ was analysed using an ANCOVA.

Time frame:
From baseline to 2 years
Reported as:
Least squares mean · units on a scale
Change in Patient-reported Symptoms
units on a scaleZemaira®Placebo
Change in Patient-reported Symptoms-1.19 ± 1.79-0.09 ± 1.93
SecondaryFrequency and Intensity of Adverse Events (AEs)

Number of participants with at least one AE, and the number of participants with mild, moderate or severe AEs. AE intensity was defined as mild (does not interfere with routine activities), moderate (interferes with routine activities), or severe (impossible to perform routine activities).

Time frame:
Over a 2-year period
Reported as:
Number · participants
Frequency and Intensity of Adverse Events (AEs)
participantsZemaira®Placebo
At least 1 AE9286
Mild AEs1316
Moderate AEs5443
Severe AEs2527
SecondaryPercent Change in Percent Predicted FEV1

Percent change from baseline to Month 24.

Time frame:
From baseline to 2 years
Reported as:
Least squares mean · percent change
Percent Change in Percent Predicted FEV1
percent changeZemaira®Placebo
Percent Change in Percent Predicted FEV1-4.16 ± 1.27-1.90 ± 1.31
SecondaryPercent Change in FEV1 Divided by Forced Vital Capacity

Percent change from baseline to Month 24.

Time frame:
From baseline to 2 years
Reported as:
Least squares mean · percent change
Percent Change in FEV1 Divided by Forced Vital Capacity
percent changeZemaira®Placebo
Percent Change in FEV1 Divided by Forced Vital Capacity-2.68 ± 1.361.56 ± 1.40
SecondaryPercent Change in DLCO

Percent change from baseline to Month 24.

Time frame:
From baseline to 2 years
Reported as:
Least squares mean · percent change
Percent Change in DLCO
percent changeZemaira®Placebo
Percent Change in DLCO-3.16 ± 1.96-1.85 ± 2.03
SecondaryDuration of Pulmonary Exacerbations Relative to Treatment Duration

Defined as the percentage of total treatment duration across participants for 1) exacerbations overall, 2) antibiotic treatment for exacerbations, and 3) hospitalization for exacerbations. Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion.

Time frame:
Over a 2-year period
Reported as:
Mean · percentage of total treatment duration
Duration of Pulmonary Exacerbations Relative to Treatment Duration
percentage of total treatment durationZemaira®Placebo
Exacerbations (n = 68, 59)77.2 ± 98.858.9 ± 109.1
Antibiotic treatment (n = 59, 52)6.32 ± 6.755.55 ± 6.80
Hospitalization (n = 19, 16)6.22 ± 8.792.16 ± 1.67
SecondarySeverity of Pulmonary Exacerbations

Defined as the number of participants requiring 1) antibiotic treatment for exacerbations, and 2) hospitalization for exacerbations. Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion. Antibiotic treatment usage was reported by quarterly interval.

Time frame:
Over a 2-year period
Reported as:
Number · participants
Severity of Pulmonary Exacerbations
participantsZemaira®Placebo
Total hospitalizations139
0 hospitalizations8078
1 hospitalization105
2 hospitalizations11
3 hospitalizations13
>3 hospitalizations10
Antibiotics: Day 1 to <Month 32219
Antibiotics: Month 3 to <Month 62920
Antibiotics: Month 6 to <Month 92415
Antibiotics: Month 9 to <Month 122117
Antibiotics: Month 12 to <Month 153021
Antibiotics: Month 15 to <Month 182115
Antibiotics: Month 18 to <Month 212615
Antibiotics: Month 21 to <Month 242015
Other pre-specifiedBaseline Lung Density at Total Lung Capacity (TLC) and Forced Residual Capacity (FRC)
Time frame:
Baseline
Reported as:
Mean · g/L
Baseline Lung Density at Total Lung Capacity (TLC) and Forced Residual Capacity (FRC)
g/LZemaira®Placebo
TLC45.5 ± 15.848.9 ± 15.5
FRC47.6 ± 15.750.7 ± 15.0

Adverse events

Collected over For the duration of the study (25 months; 1 month screening period, 24 months treatment period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zemaira®—28/93 (30.1%)90/93 (96.8%)
Placebo—28/87 (32.2%)84/87 (96.6%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventZemaira®Placebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders9/932/87
PneumoniaInfections and infestations3/934/87
Lower respiratory tract infectionInfections and infestations1/934/87
DiverticulitisInfections and infestations1/932/87
DyspnoeaRespiratory, thoracic and mediastinal disorders1/932/87
PneumothoraxRespiratory, thoracic and mediastinal disorders2/931/87
Lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/931/87
BronchitisInfections and infestations1/931/87
AppendicitisInfections and infestations0/931/87
CellulitisInfections and infestations0/931/87
Most frequent other events
Showing 10 of 41
Most frequent other events
EventZemaira®Placebo
HeadacheNervous system disorders38/9334/87
NasopharyngitisInfections and infestations30/9326/87
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders27/9319/87
Oropharyngeal painRespiratory, thoracic and mediastinal disorders22/9310/87
CoughRespiratory, thoracic and mediastinal disorders21/938/87
Condition aggravatedGeneral disorders20/9314/87
Lower respiratory tract infectionInfections and infestations18/9317/87
DyspnoeaRespiratory, thoracic and mediastinal disorders16/938/87
Upper respiratory tract infectionInfections and infestations15/9314/87
InfluenzaInfections and infestations14/9310/87

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zemaira®PlaceboTotal
Mean53.81 ± 6.19352.40 ± 7.81253.13 ± 7.374
Sex: Female, Male
Sex: Female, Male(Participants)Zemaira®PlaceboTotal
Female453782
Male485098
Baseline percent predicted forced expiratory volume in 1 second (FEV1)
Baseline percent predicted forced expiratory volume in 1 second (FEV1)(percentage)Zemaira®PlaceboTotal
Mean47.4 ± 12.147.2 ± 11.147.3 ± 11.6
Baseline diffusion capacity of carbon monoxide (DLCO)
Baseline diffusion capacity of carbon monoxide (DLCO)(mL/min/mmHg)Zemaira®PlaceboTotal
Mean13.6 ± 5.315.0 ± 5.614.3 ± 5.5
Number of participants with ZZ genotype (A1-PI deficiency), or SZ, Z / Null or Other genotype
Number of participants with ZZ genotype (A1-PI deficiency), or SZ, Z / Null or Other genotype(participants)Zemaira®PlaceboTotal
ZZ8383166
SZ202
Z / Null213
Other639
08

Study locations

28 sites
  • Study Site
    Denver, Colorado 80206, United States
  • Study Site
    Miami, Florida 33136, United States
  • Study Site
    Hershey, Pennsylvania 17033, United States
  • Study Site
    Tyler, Texas 75708, United States
  • Study Site
    Darlinghurst, New South Wales 2010, Australia
  • Study Site
    New Lambton, New South Wales 2305, Australia
  • Study Site
    Brisbane, Queensland 4066, Australia
  • Study Site
    Adelaide, South Australia 5000, Australia
  • Study Site
    Nedlands, Western Australia 6009, Australia
  • Study Site
    Fitzroy, 3065, Australia
  • Study Site
    Vancouver, British Columbia V5Z4E1, Canada
  • Study Site
    Halifax, Nova Scotia B3H3A7, Canada
  • Study Site
    Toronto, Ontario M5T2S8, Canada
  • Study Site
    Praha, 14059, Czech Republic
  • Study Site
    Arhus, 8000, Denmark
  • Study Site
    Hellerup, 2900, Denmark
  • Study Site
    Tartu, 51014, Estonia
  • Study Site
    Oulu, 90220, Finland
  • Study Site
    Berlin, 12200, Germany
  • Study Site
    Essen, 45239, Germany
  • Study Site
    Heidelberg, 69126, Germany
  • Study Site
    Nürnberg, 90419, Germany
  • Study Site
    Dublin, 9, Ireland
  • Study Site
    Krakow, 31-066, Poland
  • Study Site
    Warsaw, 01-138, Poland
  • Study Site
    Bucuresti, 011026, Romania
  • Study Site
    Barnaul, Russian Federation
  • Study Site
    Malmo, 20502, Sweden
09

References and documents

Publications

  • Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG; RAPID Trial Group. Safety of biweekly alpha1-antitrypsin treatment in the RAPID programme. Eur Respir J. 2018 Nov 29;52(5):1800897. doi: 10.1183/13993003.00897-2018. Print 2018 Nov. PubMed 30237305 ↗
  • Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jul 25;386(9991):360-8. doi: 10.1016/S0140-6736(15)60860-1. Epub 2015 May 27. PubMed 26026936 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 2 years 4 months after primary completion. A results delay was requested in Oct 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2005
First posted
Dec 5, 2005
Start
Mar 2006
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results delay requested
Oct 6, 2013
Results first posted
Jan 19, 2015
Last update
Jan 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00261833
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Dec 5, 2005
Start date
Mar 2006
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Jan 19, 2015
Last update
Jan 19, 2015

Study contacts

Senior Director Immonology & Pulmonology, Clinical R&D
study director · CSL Behring

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion